Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab in Refractory Ewing's Sarcoma
2024-514441-11-00Phase 2Authorised
- Sponsor
- Institute of Mother and Child
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of naxitamab in Ewing sarcoma of bone (2 arms), sponsored by Institute of Mother and Child. Primary endpoints: Safety and tolerability of naxitamab and Redacted primary endpoint. Planned start Aug 2024; status: authorised.
02
Drugs
naxitamab
03
Conditions
Ewing sarcoma of bone
Beyond the preview
Go deeper on 2024-514441-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514441-11-00.